These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 29168160)

  • 21. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.
    Hermann R; Karlsson MO; Novakovic AM; Terranova N; Fluck M; Munafo A
    Clin Pharmacokinet; 2019 Mar; 58(3):283-297. PubMed ID: 29987837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
    Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cladribine: mechanisms and mysteries in multiple sclerosis.
    Jacobs BM; Ammoscato F; Giovannoni G; Baker D; Schmierer K
    J Neurol Neurosurg Psychiatry; 2018 Dec; 89(12):1266-1271. PubMed ID: 29991490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 in Cladribine-treated patient with multiple sclerosis.
    Haham N; Vaknin-Dembinsky A
    J Neuroimmunol; 2021 Oct; 359():577690. PubMed ID: 34390951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double immune reconstitution therapy: Cladribine after alemtuzumab in the treatment of multiple sclerosis.
    Adamec I; Jovanović I; Krbot Skorić M; Habek M
    Eur J Neurol; 2022 Mar; 29(3):901-904. PubMed ID: 34676950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Li H; Zhang X
    N Engl J Med; 2010 May; 362(18):1738-9; author reply 1739-40. PubMed ID: 20449878
    [No Abstract]   [Full Text] [Related]  

  • 30. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
    Warnke C; Wiendl H; Hartung HP; Stüve O; Kieseier BC
    Drug Des Devel Ther; 2010 Jul; 4():117-26. PubMed ID: 20689698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
    Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A
    Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CLADIN- CLADribine and INnate immune response in multiple sclerosis - A phase IV prospective study.
    Monif M; Sequeira RP; Muscat A; Stuckey S; Sanfilippo PG; Minh V; Loftus N; Voo V; Fazzolari K; Moss M; Maltby VE; Nguyen AL; Wesselingh R; Seery N; Nesbitt C; Baker J; Dwyer C; Taylor L; Rath L; Van der Walt A; Marriott M; Kalincik T; Lechner-Scott J; O'Brien TJ; Butzkueven H
    Clin Immunol; 2024 Aug; 265():110304. PubMed ID: 38964633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cladribine for multiple sclerosis: review and current status.
    Sipe JC
    Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
    Rejdak K; Stelmasiak Z; Grieb P
    Mult Scler Relat Disord; 2019 Jan; 27():117-120. PubMed ID: 30368223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
    Oreja-Guevara C; García-Merino JA; Saiz A; Rodríguez-Antigüedad A; Álvarez-Cermeño JC; Estrada-Pérez V; Izquierdo G; Fernández O
    Rev Neurol; 2019 Dec; 69(s02):1-9. PubMed ID: 31933293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Afolabi D; Albor C; Zalewski L; Altmann DR; Baker D; Schmierer K
    Mult Scler; 2018 Oct; 24(11):1461-1468. PubMed ID: 28817997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
    Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
    Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
    Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.